NASDAQ:GWPH

GW Pharmaceuticals Stock Forecast, Price & News

$218.96
0.00 (0.00 %)
(As of 05/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$218.96
$218.96
50-Day Range
$214.36
$219.28
52-Week Range
$87.07
$219.57
VolumeN/A
Average Volume899,737 shs
Market Capitalization$6.86 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.15
30 days | 90 days | 365 days | Advanced Chart
Receive GWPH News and Ratings via Email

Sign-up to receive the latest news and ratings for GW Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GWPH
CUSIPN/A
Phone44-12-2326-6800
Employees1,161
Year FoundedN/A

Sales & Book Value

Annual Sales$311.33 million
Cash Flow$0.01 per share
Book Value$23.48 per share

Profitability

Net Income$-9,020,000.00

Debt

Price-To-Earnings

Miscellaneous

Market Cap$6.86 billion
Next Earnings Date8/5/2021 (Estimated)
OptionableOptionable

Headlines

See More Headlines
GW Pharmaceuticals logo

About GW Pharmaceuticals

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas. Its lead product is Epidiolex, an oral medicine for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of schizophrenia, autism spectrum disorder, neuropsychiatric symptom, and neonatal hypoxic ischemic encephalopathy. It primarily operates in Europe, the United Kingdom, the United States, and internationally. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.

MarketRank

Overall MarketRank

1.29 out of 5 stars

Medical Sector

830th out of 2,041 stocks

Pharmaceutical Preparations Industry

392nd out of 769 stocks

Analyst Opinion: 1.1Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











GW Pharmaceuticals (NASDAQ:GWPH) Frequently Asked Questions

Is GW Pharmaceuticals a buy right now?

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for GW Pharmaceuticals in the last twelve months. There are currently 10 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GW Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GWPH, but not buy additional shares or sell existing shares.
View analyst ratings for GW Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than GW Pharmaceuticals?

Wall Street analysts have given GW Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but GW Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting GW Pharmaceuticals?

GW Pharmaceuticals saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 659,600 shares, an increase of 67.5% from the March 15th total of 393,700 shares. Based on an average daily volume of 1,020,000 shares, the days-to-cover ratio is presently 0.6 days.
View GW Pharmaceuticals' Short Interest
.

When is GW Pharmaceuticals' next earnings date?

GW Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for GW Pharmaceuticals
.

How were GW Pharmaceuticals' earnings last quarter?

GW Pharmaceuticals plc (NASDAQ:GWPH) posted its earnings results on Sunday, May, 2nd. The biopharmaceutical company reported ($0.05) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.37) by $0.32. GW Pharmaceuticals had a negative net margin of 11.05% and a negative trailing twelve-month return on equity of 7.46%.
View GW Pharmaceuticals' earnings history
.

How has GW Pharmaceuticals' stock price been impacted by COVID-19?

GW Pharmaceuticals' stock was trading at $86.89 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, GWPH stock has increased by 152.0% and is now trading at $218.96.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for GWPH?

14 brokerages have issued 1-year price objectives for GW Pharmaceuticals' stock. Their forecasts range from $140.00 to $275.00. On average, they expect GW Pharmaceuticals' stock price to reach $204.09 in the next year. This suggests that the stock has a possible downside of 6.8%.
View analysts' price targets for GW Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are GW Pharmaceuticals' key executives?

GW Pharmaceuticals' management team includes the following people:
  • Mr. Justin D. Gover, CEO & Exec. Director (Age 50, Pay $1.19M)
  • Mr. Scott M. Giacobello, Chief Financial Officer (Age 51, Pay $743.33k)
  • Mr. Douglas B. Snyder, Chief Legal Officer & Sec. (Age 57, Pay $787.02k)
  • Dr. Volker Knappertz M.D., D.Sc., Chief Medical Officer (Age 56, Pay $830.47k)
  • Mr. Christopher John Tovey, Chief Operating Officer (Age 56)
  • Kristen Cardillo, VP of Corp. Communication
  • Ms. Tina St. Leger, Chief HR Officer
  • Prof. Ben Whalley, Head of Discovery Research
  • Mr. Darren S. Cline, U.S. Chief Commercial Officer (Age 57)

What is Justin Gover's approval rating as GW Pharmaceuticals' CEO?

14 employees have rated GW Pharmaceuticals CEO Justin Gover on Glassdoor.com. Justin Gover has an approval rating of 80% among GW Pharmaceuticals' employees.

Who are some of GW Pharmaceuticals' key competitors?

What other stocks do shareholders of GW Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GW Pharmaceuticals investors own include (CGC), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Tesla (TSLA), Intel (INTC), Netflix (NFLX), Gilead Sciences (GILD), Aurora Cannabis (ACB) and Advanced Micro Devices (AMD).

What is GW Pharmaceuticals' stock symbol?

GW Pharmaceuticals trades on the NASDAQ under the ticker symbol "GWPH."

Who are GW Pharmaceuticals' major shareholders?

GW Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Alliancebernstein L.P. (0.40%), Chicago Capital Management LLC (0.27%), Syquant Capital Sas (0.18%), Harvest Management LLC (0.14%), Commonwealth Equity Services LLC (0.07%) and CQS US LLC (0.07%). Company insiders that own GW Pharmaceuticals stock include Adam D George, Cabot Brown, Christopher J Tovey, Douglas B Snyder, Geoffrey W Dr Guy, James Noble, Julian S Gangolli, Justin D Gover, Scott M Giacobello, Volker Knappertz and William A Waldegrave.
View institutional ownership trends for GW Pharmaceuticals
.

Which major investors are selling GW Pharmaceuticals stock?

GWPH stock was sold by a variety of institutional investors in the last quarter, including Roosevelt Investment Group LLC, Greenleaf Trust, US Bancorp DE, Commonwealth Equity Services LLC, Rothschild Investment Corp IL, DekaBank Deutsche Girozentrale, Janney Montgomery Scott LLC, and Private Advisor Group LLC. Company insiders that have sold GW Pharmaceuticals company stock in the last year include Adam D George, Cabot Brown, Christopher J Tovey, Douglas B Snyder, Geoffrey W Dr Guy, Justin D Gover, and Volker Knappertz.
View insider buying and selling activity for GW Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying GW Pharmaceuticals stock?

GWPH stock was acquired by a variety of institutional investors in the last quarter, including Chicago Capital Management LLC, Alliancebernstein L.P., Syquant Capital Sas, Harvest Management LLC, CQS US LLC, Havens Advisors LLC, BCK Capital Management LP, and Dowling & Yahnke LLC.
View insider buying and selling activity for GW Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of GW Pharmaceuticals?

Shares of GWPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is GW Pharmaceuticals' stock price today?

One share of GWPH stock can currently be purchased for approximately $218.96.

How much money does GW Pharmaceuticals make?

GW Pharmaceuticals has a market capitalization of $6.86 billion and generates $311.33 million in revenue each year. The biopharmaceutical company earns $-9,020,000.00 in net income (profit) each year or ($0.24) on an earnings per share basis.

How many employees does GW Pharmaceuticals have?

GW Pharmaceuticals employs 1,161 workers across the globe.

What is GW Pharmaceuticals' official website?

The official website for GW Pharmaceuticals is www.gwpharm.com.

Where are GW Pharmaceuticals' headquarters?

GW Pharmaceuticals is headquartered at SOVEREIGN HOUSE VISION PARK HISTON, CAMBRIDGE X0, CB24 9BZ.

How can I contact GW Pharmaceuticals?

GW Pharmaceuticals' mailing address is SOVEREIGN HOUSE VISION PARK HISTON, CAMBRIDGE X0, CB24 9BZ. The biopharmaceutical company can be reached via phone at 44-12-2326-6800 or via email at [email protected]


This page was last updated on 5/7/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.